Hassan Bitar, MD
Neuromusculoskeletal Medicine & OMM · Brandon, FLNPI 1699724450
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 676 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Among neuromusculoskeletal medicine & omm clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 676 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- UCB, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Pfizer$984
- Amgen$734
- Lundbeck LLC$534
- plus $5K from 46 others
What the payments were for
- Speaking & faculty fees$200%
- Food & beverage$11,57899%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZTLido$107
How this compares
$11,678 in reported general payments places this provider in the 95th percentile of 41 neuromusculoskeletal medicine & omm providers in Florida.
See all neuromusculoskeletal medicine & omm providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RebifInterferon Beta-1a/Albumin | 12 | $213,600 |
| IngrezzaValbenazine Tosylate | 11 | $122,290 |
| Aimovig AutoinjectorErenumab-Aooe | 76 | $74,171 |
| QuliptaAtogepant | 41 | $46,125 |
| Nurtec OdtRimegepant Sulfate | 41 | $44,013 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 39 | $43,394 |
| NayzilamMidazolam | 16 | $40,870 |
| BotoxOnabotulinumtoxina | 31 | $39,297 |
| UbrelvyUbrogepant | 33 | $33,320 |
| FycompaPerampanel | 16 | $29,611 |
| RytaryCarbidopa/Levodopa | 32 | $29,166 |
| AptiomEslicarbazepine Acetate | 14 | $20,181 |
| Memantine Hcl | 804 | $16,703 |
| Rivastigmine | 61 | $11,274 |
| Levetiracetam | 381 | $10,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $244 | $213,60012 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $322 | $122,29011 claims |
| AbbVieQulipta, Botox, Ubrelvy | $2,289 | $118,741105 claims |
| PfizerNurtec Odt | $984 | $44,01341 claims |
| UCB, Inc.Nayzilam | $1,038 | $40,87016 claims |
| Eisai Inc.Fycompa | $237 | $29,61116 claims |
| Amneal Pharmaceuticals LLCRytary | $102 | $29,16632 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $265 | $20,18114 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $426 | $4,16112 claims |
| Upsher-smith Laboratories LLCTopiramate | $65 | $1,967166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 neuromusculoskeletal medicine & omm providers in Florida.
Other neuromusculoskeletal medicine & omm in Brandon
- Patricio EspinosaBoca Raton$245K
- Mohamad SalehTemple Terrace$11K
- Issachar DevineLake Mary$6K
- Ramon Lugo-SanchezMiramar$6K
- Chitto SarkarPort St Lucie$2K
- Glenn ChapmanBoynton Beach$2K
- Jesse KemmerlinSouth Miami$2K
- Jonathan QuinonezRiverview$1K
- Joel SteinFort Lauderdale$1K
- Xiawei ZhongOrlando$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.